Selected article for: "HCV vaccine development and leading cause"
Author: Brian G. Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A. Toth; Richard A. Urbanowicz; Johnathan D. Guest; Pragati Agnihotri; Melissa C. Kerzic; Alexander Marin; Alexander K. Andrianov; Jonathan K. Ball; Roy A. Mariuzza; Thomas R. Fuerst; Steven K.H. Foung
Title: Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization
  • Document date: 2020_4_17
    • ID: b6to1v4u_3
    Snippet: Hepatitis C virus (HCV) infection is a major global disease burden, with 71 million individuals, or approximately 1% of the global population, chronically infected worldwide, and 1.75 million new infections per year (1). Chronic HCV infection can lead to cirrhosis and hepatocellular carcinoma, the leading cause of liver cancer, and in the United States HCV was found to surpass HIV and 59 other infectious conditions as a cause of death (2) . While.....
    Document: Hepatitis C virus (HCV) infection is a major global disease burden, with 71 million individuals, or approximately 1% of the global population, chronically infected worldwide, and 1.75 million new infections per year (1). Chronic HCV infection can lead to cirrhosis and hepatocellular carcinoma, the leading cause of liver cancer, and in the United States HCV was found to surpass HIV and 59 other infectious conditions as a cause of death (2) . While the development of directacting antivirals has improved treatment options considerably, several factors impede the effective use of antiviral treatment such as the high cost of antivirals, viral resistance, occurrence of reinfections after treatment cessation, and lack of awareness of infection in many individuals since HCV infection is considered a silent epidemic. Therefore, development of an effective preventative vaccine for HCV is necessary to reduce the burden of infection and transmission, and for global elimination of HCV (3) .

    Search related documents:
    Co phrase search for related documents
    • antiviral treatment and death cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • antiviral treatment and global disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral treatment and global population: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antiviral treatment and HCV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • antiviral treatment and hepatocellular carcinoma cirrhosis: 1, 2
    • chronic HCV infection and global disease: 1
    • chronic HCV infection and global population: 1, 2, 3, 4
    • chronic HCV infection and HCV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • chronic HCV infection and hepatocellular carcinoma cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • death cause and global disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • death cause and global disease burden: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • death cause and global elimination: 1
    • death cause and global population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • death cause and hepatocellular carcinoma cirrhosis: 1, 2
    • effective HCV preventative vaccine and global elimination: 1
    • effective HCV preventative vaccine and HCV infection: 1
    • effective HCV preventative vaccine and HCV preventative vaccine: 1
    • global disease and HCV infection: 1, 2, 3
    • global disease burden and HCV infection: 1